AstraZeneca continues its ambition to redefine cancer care by unveiling new data at the American Society of Clinical Oncology (ASCO) annual meeting from May 31 to June 4, 2024.

More than 100 abstracts will present 25 new drugs. Several presentations will highlight significant survival results for Tagrisso and Imfinzi in various lung cancer settings.

The laboratory will also present results from a Phase III trial of Enhertu (trastuzumab deruxtecan) for HER2-low and HER2-ultralow metastatic breast cancer, HR-positive after endocrine therapy, as well as the 1st-in-man trial of C-CAR031, a CAR-T therapy targeting Glypican 3 (GPC3) for liver cancer.

CEOs Dave Fredrickson and Susan Galbraith highlighted advances in lung cancer treatments and the possibility of replacing traditional chemotherapy with antibody-drug conjugates.

Copyright (c) 2024 All rights reserved.